We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(STAT Plus) Feb 23, 2017 - It’s estimated that more than 13,000 new cases of laryngeal cancer will be diagnosed this year — some of which will cost patients all or part of the voice boxes — but new research using stem cells aims to save their speech by growing new larynges right in the lab.
(CancerConnect.com) Feb 23, 2017 - OMNI Health Media (OMNI) announces the launch of a new online community on CancerConnect for individuals with neuroendocrine tumors (NET). This community will provide patients and their loved ones with information and support.
(Cold Spring Harbor Laboratory) Feb 23, 2017 - Distinct cellular subtypes in dense tumor-enveloping stroma may be precisely targeted to improve treatment response.
(NPR/Shots blog) Feb 24, 2017 - Many studies designed to try out new drugs simply languish. They don't attract enough patients, and they aren't completed. Here's a story of one study that bucked that trend.
(MD Anderson) Feb 23, 2017 - Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma, an often fatal form of brain cancer, according to researchers at The University of Texas MD Anderson Cancer Center.
(WBMA-TV/ABC [Birmingham, AL]) Feb 23, 2017 - The cost of cancer care is exploding. Doctors say it will continue to be a problem for the next decade or two. Dr. Ed Partridge, the Director of UAB's Comprehensive Cancer Center says a significant amount of bankruptcies are related to cancer care.
(The Business Journals) Feb 23, 2017 - Top-line results anticipated 1H 2018.
(STAT Plus) Feb 23, 2017 - The drug industry is going all-in on its push to shift the conversation about drug prices to one about value, and its top lobbyist said the industry would be opportunistic in the coming months in finding legislative and administrative avenues to advance policies in pursuit of that goal.
(Yahoo! Finance) Feb 23, 2017 - MabVax Therapeutics Holdings, Inc. announces that it has received notice from the U.S. Food and Drug Administration (FDA) authorizing the initiation a Phase I clinical trial with MVT-1075 as a therapeutic treatment for pancreatic cancer. MVT-1075 (177Lu-CHX-A″-DTPA-HuMab5B1) is the Company's novel fully human antibody radioimmunotherapy (RIT).
(ProPublica) Feb 23, 2017 - As it readies for battle with President Trump over drug prices, the pharmaceutical industry is deploying economists and health care experts from the nation’s top universities. In scholarly articles, blogs and conferences, they lend their prestige to the lobbying blitz, without always disclosing their corporate ties.